Market Spotlight: Hodgkin’s Lymphoma
Market Spotlight: Hodgkin’s Lymphoma
$1,318.00
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, regulatory events, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 80,800 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.
- In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.
- The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/TNFRSF8, microtubules (tubulin), DNA, the immune system, and programmed death-1 receptor/programmed death ligands (PD-L1 and PD-L2). The majority of the approved drugs are administered via the intravenous route.
- Industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are spread evenly across Phase I and Phase II, with no drugs in Phase III.
- Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral, intratumoral, and subcutaneous formulations.
- The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 58.5%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 56 trials.
- Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin’s lymphoma, followed by Bristol Myers Squibb.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Chemotherapy
10 Radiation therapy
10 Immunotherapy
11 Stem cell transplantation (SCT)
12 EPIDEMIOLOGY
16 MARKETED DRUGS
20 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 AFM13 for Hodgkin’s Lymphoma (April 9, 2021)
26 Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020)
28 Keytruda for Hodgkin’s Lymphoma (May 13, 2020)
31 KEY REGULATORY EVENTS
31 Zimberelimab Receives Approval In China For Hodgkin’s Lymphoma
31 China Approves Fifth Domestic PD-1 Drug
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
33 Daiichi’s Novel EZH Candidate Progresses In New Consortium Trial
33 BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
34 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
39 Recent events
40 BIBLIOGRAPHY
41 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of Hodgkin’s lymphoma, 2019–28
20 Figure 2: Overview of pipeline drugs for Hodgkin’s lymphoma in the US
20 Figure 3: Pipeline drugs for Hodgkin’s lymphoma, by company
21 Figure 4: Pipeline drugs for Hodgkin’s lymphoma, by drug type
21 Figure 5: Pipeline drugs for Hodgkin’s lymphoma, by classification
26 Figure 6: AFM13 for Hodgkin’s Lymphoma (April 9, 2021): Phase I – University of Texas
28 Figure 7: Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020): Phase II – R/R HL
30 Figure 8: Keytruda for Hodgkin’s Lymphoma (May 13, 2020): Phase III – KEYNOTE-204
32 Figure 9: Probability of success in the hematologic pipeline
36 Figure 10: Clinical trials in Hodgkin’s lymphoma
36 Figure 11: Top 10 drugs for clinical trials in Hodgkin’s lymphoma
37 Figure 12: Top 10 companies for clinical trials in Hodgkin’s lymphoma
37 Figure 13: Trial locations in Hodgkin’s lymphoma
38 Figure 14: Hodgkin’s lymphoma trials status
39 Figure 15: Hodgkin’s lymphoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of Hodgkin’s lymphoma, 2019–28
15 Table 2: Five-year prevalent cases of Hodgkin’s lymphoma, 2019–28
17 Table 3: Marketed drugs for Hodgkin’s lymphoma
22 Table 4: Pipeline drugs for Hodgkin’s lymphoma in the US
25 Table 5: AFM13 for Hodgkin’s Lymphoma (April 9, 2021)
27 Table 6: Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020)
29 Table 7: Keytruda for Hodgkin’s Lymphoma (May 13, 2020)
34 Table 8: Historical global sales, by drug ($m), 2016–20
35 Table 9: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Primary Sclerosing Cholangitis (PSC) 
Sign up to the